MX2021003450A - Metodos para tratar trastornos mieloproliferativos. - Google Patents

Metodos para tratar trastornos mieloproliferativos.

Info

Publication number
MX2021003450A
MX2021003450A MX2021003450A MX2021003450A MX2021003450A MX 2021003450 A MX2021003450 A MX 2021003450A MX 2021003450 A MX2021003450 A MX 2021003450A MX 2021003450 A MX2021003450 A MX 2021003450A MX 2021003450 A MX2021003450 A MX 2021003450A
Authority
MX
Mexico
Prior art keywords
methods
myeloproliferative disorders
treating myeloproliferative
treating
disorders
Prior art date
Application number
MX2021003450A
Other languages
English (en)
Spanish (es)
Inventor
John Hood
Tymara Berry
Catriona Jamieson
Curtis L Scribner
Original Assignee
Impact Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69950867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021003450(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Impact Biomedicines Inc filed Critical Impact Biomedicines Inc
Publication of MX2021003450A publication Critical patent/MX2021003450A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MX2021003450A 2018-09-25 2019-09-24 Metodos para tratar trastornos mieloproliferativos. MX2021003450A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862736369P 2018-09-25 2018-09-25
US201862783076P 2018-12-20 2018-12-20
PCT/US2019/052608 WO2020068755A1 (en) 2018-09-25 2019-09-24 Methods of treating myeloproliferative disorders

Publications (1)

Publication Number Publication Date
MX2021003450A true MX2021003450A (es) 2021-07-16

Family

ID=69950867

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021003450A MX2021003450A (es) 2018-09-25 2019-09-24 Metodos para tratar trastornos mieloproliferativos.
MX2023013844A MX2023013844A (es) 2018-09-25 2021-03-24 Metodos para tratar trastornos mieloproliferativos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023013844A MX2023013844A (es) 2018-09-25 2021-03-24 Metodos para tratar trastornos mieloproliferativos.

Country Status (14)

Country Link
US (2) US20220031699A1 (cg-RX-API-DMAC7.html)
EP (1) EP3856169A4 (cg-RX-API-DMAC7.html)
JP (2) JP7856429B2 (cg-RX-API-DMAC7.html)
KR (2) KR20210102192A (cg-RX-API-DMAC7.html)
CN (1) CN113286584A (cg-RX-API-DMAC7.html)
AU (1) AU2019346521B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021005518A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021000744A1 (cg-RX-API-DMAC7.html)
IL (1) IL281736A (cg-RX-API-DMAC7.html)
MA (1) MA53741A (cg-RX-API-DMAC7.html)
MX (2) MX2021003450A (cg-RX-API-DMAC7.html)
MY (1) MY209349A (cg-RX-API-DMAC7.html)
SG (1) SG11202103019WA (cg-RX-API-DMAC7.html)
WO (1) WO2020068755A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010363329A1 (en) * 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
MA53745A (fr) * 2018-09-25 2021-08-04 Impact Biomedicines Inc Procédés de traitement de troubles myéloprolifératifs
MY209349A (en) 2018-09-25 2025-07-03 Impact Biomedicines Inc Methods of treating myeloproliferative disorders
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor
EP4262770A1 (en) * 2020-12-16 2023-10-25 Impact Biomedicines, Inc. Dosing of fedratinib
EP4297750A1 (en) 2021-02-25 2024-01-03 Impact Biomedicines, Inc. Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis
US20240358722A1 (en) * 2021-09-14 2024-10-31 Impact Biomedicines, Inc. Methods of administering fedratinib

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
WO2007053452A1 (en) * 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US20090093009A1 (en) * 2007-10-09 2009-04-09 Sum Chan Mass spectrometry method for measuring thiamine in body fluid
AU2010363329A1 (en) * 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
US20130102624A1 (en) * 2011-05-19 2013-04-25 John V. Schloss Early detection of thiamine deficiency
US10155987B2 (en) 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
WO2015081127A2 (en) 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
MX2016009974A (es) * 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
WO2017024171A1 (en) * 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
MA53745A (fr) 2018-09-25 2021-08-04 Impact Biomedicines Inc Procédés de traitement de troubles myéloprolifératifs
MY209349A (en) 2018-09-25 2025-07-03 Impact Biomedicines Inc Methods of treating myeloproliferative disorders
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor
FR3092581A1 (fr) 2019-02-12 2020-08-14 Impact Biomedicines, Inc Formes cristallines d'un inhibiteur de jak2

Also Published As

Publication number Publication date
US20220031699A1 (en) 2022-02-03
CL2021000744A1 (es) 2021-10-08
JP2022502492A (ja) 2022-01-11
AU2019346521B2 (en) 2025-05-08
US20220133724A1 (en) 2022-05-05
BR112021005518A2 (pt) 2021-06-29
JP2024161416A (ja) 2024-11-19
MA53741A (fr) 2021-08-04
IL281736A (en) 2021-05-31
MX2023013844A (es) 2023-12-08
JP7856429B2 (ja) 2026-05-11
KR20250164332A (ko) 2025-11-24
WO2020068755A1 (en) 2020-04-02
KR20210102192A (ko) 2021-08-19
US11400092B2 (en) 2022-08-02
AU2019346521A1 (en) 2021-05-20
EP3856169A4 (en) 2022-06-29
MY209349A (en) 2025-07-03
CN113286584A (zh) 2021-08-20
SG11202103019WA (en) 2021-04-29
EP3856169A1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
CL2021000744A1 (es) Métodos para tratar trastornos mieloproliferativos
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
MX2021010198A (es) Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
CO2018012946A2 (es) Moduladores de la vía de estrés integrada
CR20170011A (es) Compuestos de heteroarilo para la inhibición de cinasa
MX377141B (es) Composiciones y metodos para modular la expresion de pkk.
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
UY36716A (es) Moduladores de receptores nucleares
MX2018000778A (es) Metodos para tratar trastornos mediados por hepcidinas.
MX2022002446A (es) Compuestos de pirrolopirimidina inhibidores de perk.
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
MX2020002435A (es) Agentes que modulan las funciones de beta-catenina y sus métodos.
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
JOP20220042A1 (ar) طرق لعلاج فرط فينيل ألانين الدم
MX386146B (es) Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
BR112017025263A2 (pt) método para o tratamento de doença neurológica
SG11202105279SA (en) Methods of treating myeloproliferative disorders
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
MX2022013383A (es) Composiciones y metodo para tratar la depresion.
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors
EP3856189A4 (en) Methods of treating myeloproliferative disorders
MX374705B (es) Composiciones que comprenden anakinra.